NCT03114215View on ClinicalTrials.gov

Effect of MD1003 in Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

June 12, 2017

Study Completion Date

December 31, 2017

Conditions
ALSAmyotrophic Lateral SclerosisMotor Neuron Disease
Interventions
DRUG

MD1003

capsules 100mg 3 times per day

DRUG

Placebo oral capsule

capsules 100mg lactose 3 times per day

Trial Locations (1)

34000

Hopital Gui De Chauliac, Montpellier

Sponsors
All Listed Sponsors
lead

MedDay Pharmaceuticals SA

INDUSTRY

NCT03114215 - Effect of MD1003 in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter